Three-year longitudinal assessment of denosumab’s efficacy and safety in postmenopausal osteoporosis: a 36-month real-world cohort study - Top-Institutions - MDSpire

Three-year longitudinal assessment of denosumab’s efficacy and safety in postmenopausal osteoporosis: a 36-month real-world cohort study

  • By

  • Rong-Lin Xia

  • Chen Li

  • Li Wang

  • Ai-Jun Chao

  • Wei Wei

  • July 14, 2026

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Tianjin Hospital
    Tianjin Hospital

    Tianjin, Tianjin

    Key Differentiators

    • Endocrinology

  • #2

    Mass General Brigham
    Mass General Brigham

    Boston, Massachusetts

    Key Differentiators

    • Endocrinology

  • #3

    Aarhus University Hospital
    Aarhus University Hospital

    Aarhus, Central Jutland

    Key Differentiators

    • Endocrinology

Original Source(s)

Three-year longitudinal assessment of denosumab’s efficacy and safety in postmenopausal osteoporosis: a 36-month real-world cohort study

  • by Rong-Lin Xia, Chen Li, Li Wang, Ai-Jun Chao, Wei Wei

  • July 14, 2026

Related Content

Serum adropin as a potential renoprotective factor in diabetic kidney disease: evidence from a Chinese elderly cohort and an experimental mouse model

The role of hypoglycemic phytochemicals in improving male reproductive dysfunction: a systematic review of preclinical evidence

Targeting macrophage metabolism: mechanisms, cellular crosstalk and implications in obesity-associated metabolic diseases